AAPL331.90-6.42 (-1.90%) ▼|ABBV286.00-2.84 (-0.98%) ▼|ABT109.40-0.76 (-0.69%) ▼|ACN254.56-6.38 (-2.45%) ▼|ADBE246.14-5.33 (-2.12%) ▼|AMAT381.92+7.39 (+1.97%) ▲|AMD483.90+17.06 (+3.65%) ▲|AMGN461.26-4.19 (-0.90%) ▼|AMT187.29-1.01 (-0.54%) ▼|AMZN250.69+5.06 (+2.06%) ▲|AVGO332.13+9.90 (+3.07%) ▲|AXP325.50-2.48 (-0.76%) ▼|BA173.31-2.09 (-1.19%) ▼|BAC49.66+0.09 (+0.18%) ▲|BKNG155.67+1.92 (+1.25%) ▲|BLK1,161.32-5.83 (-0.50%) ▼|BMY61.71-1.31 (-2.08%) ▼|BNY149.31+1.53 (+1.04%) ▲|BRK-B557.07+0.96 (+0.17%) ▲|C122.71-0.39 (-0.32%) ▼|CAT623.94+10.32 (+1.68%) ▲|CL95.62-1.81 (-1.86%) ▼|CMCSA23.67-0.20 (-0.84%) ▼|COF208.71-2.06 (-0.98%) ▼|COP144.40-2.44 (-1.66%) ▼|COST1,019.26-21.29 (-2.05%) ▼|CRM222.20-3.98 (-1.76%) ▼|CSCO102.97+1.36 (+1.34%) ▲|CVS91.41+2.90 (+3.28%) ▲|CVX225.27-2.50 (-1.10%) ▼|DE665.83-1.77 (-0.27%) ▼|DHR230.11+2.14 (+0.94%) ▲|DIS114.18+1.07 (+0.95%) ▲|DUK126.51-1.87 (-1.46%) ▼|EMR166.39+0.43 (+0.26%) ▲|FDX318.02-0.23 (-0.07%) ▼|GD374.50+1.04 (+0.28%) ▲|GE320.67+4.89 (+1.55%) ▲|GEV918.20+55.95 (+6.49%) ▲|GILD167.47-2.86 (-1.68%) ▼|GM88.34-1.60 (-1.78%) ▼|GOOG278.27+0.23 (+0.08%) ▲|GOOGL280.03+1.04 (+0.37%) ▲|GS896.09-2.63 (-0.29%) ▼|HD333.66-7.49 (-2.20%) ▼|HON224.05+0.28 (+0.13%) ▲|IBM250.04-2.47 (-0.98%) ▼|INTC60.55+0.58 (+0.97%) ▲|INTU344.72-7.38 (-2.10%) ▼|ISRG440.75+3.88 (+0.89%) ▲|JNJ266.17-4.39 (-1.62%) ▼|JPM337.98-2.60 (-0.76%) ▼|KO94.80-1.03 (-1.07%) ▼|LIN511.55-8.17 (-1.57%) ▼|LLY1,409.38-1.61 (-0.11%) ▼|LMT639.00-4.15 (-0.65%) ▼|LOW213.38-4.77 (-2.19%) ▼|LRCX230.72+3.16 (+1.39%) ▲|MA647.18-10.92 (-1.66%) ▼|MCD263.04-2.60 (-0.98%) ▼|MDLZ65.12-1.26 (-1.90%) ▼|MDT98.88-0.41 (-0.41%) ▼|META621.03+14.30 (+2.36%) ▲|MMM177.05-1.31 (-0.73%) ▼|MO76.94-0.23 (-0.30%) ▼|MRK144.67-3.69 (-2.49%) ▼|MS186.09+0.36 (+0.19%) ▲|MSFT520.99+13.87 (+2.74%) ▲|MU855.10+21.51 (+2.58%) ▲|NEE84.33-0.70 (-0.82%) ▼|NFLX63.42+1.08 (+1.73%) ▲|NKE38.48-0.64 (-1.64%) ▼|NOW109.16+3.15 (+2.97%) ▲|NVDA206.69+4.63 (+2.29%) ▲|ORCL126.19+6.97 (+5.85%) ▲|PEP137.27-3.15 (-2.24%) ▼|PFE30.00-0.67 (-2.18%) ▼|PG162.06-1.50 (-0.92%) ▼|PLTR175.40-2.94 (-1.65%) ▼|PM208.03-0.26 (-0.12%) ▼|QCOM164.43+2.35 (+1.45%) ▲|RTX203.82+1.03 (+0.51%) ▲|SBUX104.77+0.37 (+0.35%) ▲|SCHW89.28+0.57 (+0.64%) ▲|SO93.75-0.86 (-0.91%) ▼|SPG222.08+0.35 (+0.16%) ▲|T21.39-0.05 (-0.23%) ▼|TMO698.34+15.69 (+2.30%) ▲|TMUS154.41-5.74 (-3.58%) ▼|TSLA398.50-5.32 (-1.32%) ▼|TXN312.49+10.47 (+3.47%) ▲|UBER66.60-0.11 (-0.16%) ▼|UNH404.44+4.00 (+1.00%) ▲|UNP303.43-3.57 (-1.16%) ▼|UPS109.17-0.54 (-0.49%) ▼|USB59.89-0.60 (-0.99%) ▼|V420.42-5.09 (-1.20%) ▼|VZ45.24+0.19 (+0.42%) ▲|WFC85.53-0.36 (-0.42%) ▼|WMT124.86-2.83 (-2.22%) ▼|XOM177.46-2.21 (-1.23%) ▼|AAPL331.90-6.42 (-1.90%) ▼|ABBV286.00-2.84 (-0.98%) ▼|ABT109.40-0.76 (-0.69%) ▼|ACN254.56-6.38 (-2.45%) ▼|ADBE246.14-5.33 (-2.12%) ▼|AMAT381.92+7.39 (+1.97%) ▲|AMD483.90+17.06 (+3.65%) ▲|AMGN461.26-4.19 (-0.90%) ▼|AMT187.29-1.01 (-0.54%) ▼|AMZN250.69+5.06 (+2.06%) ▲|AVGO332.13+9.90 (+3.07%) ▲|AXP325.50-2.48 (-0.76%) ▼|BA173.31-2.09 (-1.19%) ▼|BAC49.66+0.09 (+0.18%) ▲|BKNG155.67+1.92 (+1.25%) ▲|BLK1,161.32-5.83 (-0.50%) ▼|BMY61.71-1.31 (-2.08%) ▼|BNY149.31+1.53 (+1.04%) ▲|BRK-B557.07+0.96 (+0.17%) ▲|C122.71-0.39 (-0.32%) ▼|CAT623.94+10.32 (+1.68%) ▲|CL95.62-1.81 (-1.86%) ▼|CMCSA23.67-0.20 (-0.84%) ▼|COF208.71-2.06 (-0.98%) ▼|COP144.40-2.44 (-1.66%) ▼|COST1,019.26-21.29 (-2.05%) ▼|CRM222.20-3.98 (-1.76%) ▼|CSCO102.97+1.36 (+1.34%) ▲|CVS91.41+2.90 (+3.28%) ▲|CVX225.27-2.50 (-1.10%) ▼|DE665.83-1.77 (-0.27%) ▼|DHR230.11+2.14 (+0.94%) ▲|DIS114.18+1.07 (+0.95%) ▲|DUK126.51-1.87 (-1.46%) ▼|EMR166.39+0.43 (+0.26%) ▲|FDX318.02-0.23 (-0.07%) ▼|GD374.50+1.04 (+0.28%) ▲|GE320.67+4.89 (+1.55%) ▲|GEV918.20+55.95 (+6.49%) ▲|GILD167.47-2.86 (-1.68%) ▼|GM88.34-1.60 (-1.78%) ▼|GOOG278.27+0.23 (+0.08%) ▲|GOOGL280.03+1.04 (+0.37%) ▲|GS896.09-2.63 (-0.29%) ▼|HD333.66-7.49 (-2.20%) ▼|HON224.05+0.28 (+0.13%) ▲|IBM250.04-2.47 (-0.98%) ▼|INTC60.55+0.58 (+0.97%) ▲|INTU344.72-7.38 (-2.10%) ▼|ISRG440.75+3.88 (+0.89%) ▲|JNJ266.17-4.39 (-1.62%) ▼|JPM337.98-2.60 (-0.76%) ▼|KO94.80-1.03 (-1.07%) ▼|LIN511.55-8.17 (-1.57%) ▼|LLY1,409.38-1.61 (-0.11%) ▼|LMT639.00-4.15 (-0.65%) ▼|LOW213.38-4.77 (-2.19%) ▼|LRCX230.72+3.16 (+1.39%) ▲|MA647.18-10.92 (-1.66%) ▼|MCD263.04-2.60 (-0.98%) ▼|MDLZ65.12-1.26 (-1.90%) ▼|MDT98.88-0.41 (-0.41%) ▼|META621.03+14.30 (+2.36%) ▲|MMM177.05-1.31 (-0.73%) ▼|MO76.94-0.23 (-0.30%) ▼|MRK144.67-3.69 (-2.49%) ▼|MS186.09+0.36 (+0.19%) ▲|MSFT520.99+13.87 (+2.74%) ▲|MU855.10+21.51 (+2.58%) ▲|NEE84.33-0.70 (-0.82%) ▼|NFLX63.42+1.08 (+1.73%) ▲|NKE38.48-0.64 (-1.64%) ▼|NOW109.16+3.15 (+2.97%) ▲|NVDA206.69+4.63 (+2.29%) ▲|ORCL126.19+6.97 (+5.85%) ▲|PEP137.27-3.15 (-2.24%) ▼|PFE30.00-0.67 (-2.18%) ▼|PG162.06-1.50 (-0.92%) ▼|PLTR175.40-2.94 (-1.65%) ▼|PM208.03-0.26 (-0.12%) ▼|QCOM164.43+2.35 (+1.45%) ▲|RTX203.82+1.03 (+0.51%) ▲|SBUX104.77+0.37 (+0.35%) ▲|SCHW89.28+0.57 (+0.64%) ▲|SO93.75-0.86 (-0.91%) ▼|SPG222.08+0.35 (+0.16%) ▲|T21.39-0.05 (-0.23%) ▼|TMO698.34+15.69 (+2.30%) ▲|TMUS154.41-5.74 (-3.58%) ▼|TSLA398.50-5.32 (-1.32%) ▼|TXN312.49+10.47 (+3.47%) ▲|UBER66.60-0.11 (-0.16%) ▼|UNH404.44+4.00 (+1.00%) ▲|UNP303.43-3.57 (-1.16%) ▼|UPS109.17-0.54 (-0.49%) ▼|USB59.89-0.60 (-0.99%) ▼|V420.42-5.09 (-1.20%) ▼|VZ45.24+0.19 (+0.42%) ▲|WFC85.53-0.36 (-0.42%) ▼|WMT124.86-2.83 (-2.22%) ▼|XOM177.46-2.21 (-1.23%) ▼|
13.4 C
New York
Wednesday, November 4, 2026

Tag: BIO PHA MTC HEA

newsFORsourcecompanycontentinformationreleases1market

Biocon Malaysia Recognised Across Five Categories at MOPI Pharma Industry Awards 2026

JOHOR BAHRU, Malaysia, Nov. 4, 2026 /PRNewswire/ -- Biocon Sdn. Bhd., Malaysia (Biocon Malaysia), a stepdown subsidiary of global biopharmaceuticals company Biocon Limited, has...

Samsung Biologics Achieves ‘Negligible Risk’ Rating in Sustainalytics ESG Assessment

Earns ESG Risk Rating score of 9.0, ranking among the top 0.5% in the pharmaceuticals industryAdvances from 'Low Risk' to 'Negligible Risk,' the lowest...

Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation

Preliminary responses observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumabEarly antitumor activity also...

Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or "Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific...

From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment

Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International ReachSHANGHAI and MADRID, Oct. 28, 2026 /PRNewswire/ -- The European Society for...

CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity

CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tumorsHighlightsThree pillars...

ESMO 2026 | Professors Jie Wang, Zhijie Wang and Jianchun Duan’s Team Reports 95.2% Disease Control With LK101 Combination Maintenance Therapy in Advanced NSCLC

BEIJING, Oct. 25, 2026 /PRNewswire/ -- On October 24, 2026, in Madrid, Spain, the team of Professors Jie Wang, Zhijie Wang and Jianchun Duan at...

Results of CARsgen’s Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026

SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development,...

2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research,...

Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

-  At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and...

Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026

Data updates from the ongoing Phase 1 dose-escalation study demonstrated promising therapeutic index in patients with mCRPCNo dose-limiting toxicities observed; xerostomia has been predominantly...

Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection)

- Global cure observed in 83.3% of LMN-201 recipients versus 36.4% randomized to placebo- LMN-201 treatment plus standard-of-care antibiotics demonstrated a six-fold reduction in...

Arctic Therapeutics closes oversubscribed US$21.5 million financing

The financing round, led by investment firm Pekron, Investcorp-backed Sanos Group, Icelandic investment company Kaldbakur and Landvættir, an Icelandic venture capital fund managed by...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBIO PHA MTC HEA

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers